Literature DB >> 23289677

Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field.

Leili Fatehi1, Susan M Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P Kahn, Cortney Jones, Stephen A Campbell, Rebecca S Dresser, Arthur G Erdman, Christy L Haynes, Robert A Hoerr, Linda F Hogle, Moira A Keane, George Khushf, Nancy M P King, Efrosini Kokkoli, Gary Marchant, Andrew D Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A Siegel, Samuel Wickline.   

Abstract

The nanomedicine field is fast evolving toward complex, "active," and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an occasion to think systematically about appropriate oversight, especially early in the evolution of a technology, when hazard and risk information may remain incomplete. This paper presents the consensus recommendations of a multidisciplinary, NIH-funded project group, to ensure a science-based and ethically informed approach to HSR issues in nanomedicine, and to integrate HSR analysis with analysis of occupational, bystander, and environmental concerns. We recommend creating two bodies, an interagency Human Subjects Research in Nanomedicine (HSR/N) Working Group and a Secretary's Advisory Committee on Nanomedicine (SAC/N). HSR/N and SAC/N should perform 3 primary functions: (1) analysis of the attributes and subsets of nanomedicine interventions that raise HSR challenges and current gaps in oversight; (2) providing advice to relevant agencies and institutional bodies on the HSR issues, as well as federal and federal-institutional coordination; and (3) gathering and analyzing information on HSR issues as they emerge in nanomedicine. HSR/N and SAC/N will create a home for HSR analysis and coordination in DHHS (the key agency for relevant HSR oversight), optimize federal and institutional approaches, and allow HSR review to evolve with greater knowledge about nanomedicine interventions and greater clarity about attributes of concern.
© 2012 American Society of Law, Medicine & Ethics, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23289677      PMCID: PMC4467171          DOI: 10.1111/j.1748-720X.2012.00703.x

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.718


  61 in total

1.  Therapeutic misconception and the appreciation of risks in clinical trials.

Authors:  Charles W Lidz; Paul S Appelbaum; Thomas Grisso; Michelle Renaud
Journal:  Soc Sci Med       Date:  2004-05       Impact factor: 4.634

2.  Nanomedicine-emerging or re-emerging ethical issues? A discussion of four ethical themes.

Authors:  Christian Lenk; Nikola Biller-Andorno
Journal:  Med Health Care Philos       Date:  2006-08-30

Review 3.  Nanomedicine: An unresolved regulatory issue.

Authors:  Vivian S W Chan
Journal:  Regul Toxicol Pharmacol       Date:  2006-11-01       Impact factor: 3.271

Review 4.  Multifunctional nanoparticles--properties and prospects for their use in human medicine.

Authors:  Nuria Sanvicens; M Pilar Marco
Journal:  Trends Biotechnol       Date:  2008-08       Impact factor: 19.536

5.  Managing the "known unknowns": theranostic cancer nanomedicine and informed consent.

Authors:  Fabrice Jotterand; Archie A Alexander
Journal:  Methods Mol Biol       Date:  2011

6.  Designing Oversight for Nanomedicine Research in Human Subjects: Systematic Analysis of Exceptional Oversight for Emerging Technologies.

Authors:  Susan M Wolf; Cortney Jones
Journal:  J Nanopart Res       Date:  2011-04       Impact factor: 2.253

Review 7.  Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

Authors:  Robert Kinders; Ralph E Parchment; Jay Ji; Shivaani Kummar; Anthony J Murgo; Martin Gutierrez; Jerry Collins; Larry Rubinstein; Oxana Pickeral; Seth M Steinberg; Sherry Yang; Melinda Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Mel Simpson; Joseph E Tomaszewski; James H Doroshow
Journal:  Mol Interv       Date:  2007-12

8.  Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes.

Authors:  D C Litzinger; A M Buiting; N van Rooijen; L Huang
Journal:  Biochim Biophys Acta       Date:  1994-02-23

9.  Ethics and Nanopharmacy: Value Sensitive Design of New Drugs.

Authors:  Job Timmermans; Yinghuan Zhao; Jeroen van den Hoven
Journal:  Nanoethics       Date:  2011-11-09       Impact factor: 0.917

Review 10.  Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles.

Authors:  Günter Oberdörster; Eva Oberdörster; Jan Oberdörster
Journal:  Environ Health Perspect       Date:  2005-07       Impact factor: 9.031

View more
  6 in total

1.  Rethinking risk assessment for emerging technology first-in-human trials.

Authors:  Anna Genske; Sabrina Engel-Glatter
Journal:  Med Health Care Philos       Date:  2016-03

Review 2.  Peripheral Nerve Nanoimaging: Monitoring Treatment and Regeneration.

Authors:  Jelena M Janjic; Vijay S Gorantla
Journal:  AAPS J       Date:  2017-08-04       Impact factor: 4.009

Review 3.  Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

Authors:  Fatemeh Farjadian; Amir Ghasemi; Omid Gohari; Amir Roointan; Mahdi Karimi; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2018-11-19       Impact factor: 5.307

4.  Stakeholder views on participant selection for first-in-human trials in cancer nanomedicine.

Authors:  P Satalkar; B S Elger; D M Shaw
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

Review 5.  Crossing the barrier: treatment of brain tumors using nanochain particles.

Authors:  Efstathios Karathanasis; Ketan B Ghaghada
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-09

6.  Introduction: the challenge of nanomedicine human subjects research: protecting participants, workers, bystanders, and the environment.

Authors:  Susan M Wolf
Journal:  J Law Med Ethics       Date:  2012       Impact factor: 1.718

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.